SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001811764-23-000031
Filing Date
2023-08-03
Accepted
2023-08-03 16:05:16
Documents
14
Period of Report
2023-07-28
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pnt-20230728.htm   iXBRL 8-K 36115
2 EX-16.1 pointbiopharmaglobalincl.htm EX-16.1 1303
6 pointbiopharmaglobalincl001.jpg GRAPHIC 76478
  Complete submission text file 0001811764-23-000031.txt   270627

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT pnt-20230728.xsd EX-101.SCH 1919
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT pnt-20230728_lab.xml EX-101.LAB 23876
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT pnt-20230728_pre.xml EX-101.PRE 12533
8 EXTRACTED XBRL INSTANCE DOCUMENT pnt-20230728_htm.xml XML 2731
Mailing Address 4850 WEST 78TH STREET INDIANAPOLIS IN 46268
Business Address 4850 WEST 78TH STREET INDIANAPOLIS IN 46268 (317) 543-9957
POINT Biopharma Global Inc. (Filer) CIK: 0001811764 (see all company filings)

IRS No.: 850800493 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39373 | Film No.: 231139836
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences